Eargo和hearX完成合并，宣布新成立的联合公司LXE Hearing-动脉网

Eargo and hearX Close Merger, Announce New Combined Company, LXE Hearing

CISION 等信源发布 2025-04-01 01:15



可切换为仅中文







Two national hearing health brands combine to make high-quality hearing aids more accessible and affordable for the estimated 44 million American adults with hearing loss

两大全国听力健康品牌联手，为美国约4400万听损成年人提供更易获取且更实惠的高品质助听器。

First notable merger in the over-the-counter hearing aid

首次在非处方助听器领域的显著合并

space since the FDA's 2022 regulations that allowed for the sale of over-the-counter hearing aids

自 FDA 2022 年允许销售非处方助听器的规定以来的空间

The new company will receive

新公司将会接收

$100 million

1亿美元

in funding from Patient Square Capital, a dedicated health care investment firm

来自专注于医疗保健的投资公司Patient Square Capital的资金支持

SAN JOSE, Calif.

加利福尼亚州圣何塞

，

March 31, 2025

2025年3月31日

/PRNewswire/ -- Hearing health pioneers Eargo and hearX, maker of Lexie hearing aids, announced today that they have completed their merger, resulting in the creation of a combined company called LXE Hearing. Backed by an additional

/PRNewswire/ -- 听力健康领域的先驱企业Eargo和生产Lexie助听器的hearX今天宣布，他们已完成合并，由此创建了一家名为LXE Hearing的联合公司。新公司还获得了额外的资金支持。

$100 million

1亿美元

investment from Patient Square Capital, the deal creates a new hearing health company and is the first notable combination for the over-the-counter (OTC) hearing aid market since the FDA established the regulatory category in 2022.

来自Patient Square Capital的投资，这笔交易创建了一家新的听力健康公司，也是自FDA于2022年设立非处方（OTC）助听器监管类别以来，该市场的首次显著合并。

继续阅读

LXE Hearing Executive Management

LXE听证会执行管理

LXE Hearing will operate as one company with its two established consumer hearing aid brands, Eargo and

LXE听力公司将与其两个已建立的消费类助听器品牌Eargo和

Lexie Hearing

Lexie听力

. With a collective 25 years of experience as hearing health innovators, LXE Hearing is looking to set a new standard for the industry that marries Eargo's and Lexie's award-winning credentials in design, device features, sound technology and mobile platforms–against the background of the company's customer-first ethos. LXE Hearing will also be combining product technology platforms and Customer Relationship Management systems to create a more streamlined experience for all their business partners..

凭借作为听力健康创新者累积25年的经验，LXE Hearing致力于为行业设立新标准，将Eargo和Lexie在设计、设备功能、声音技术和移动平台方面的获奖资质与公司以客户为先的理念相结合。LXE Hearing还将整合产品技术平台和客户关系管理系统，为所有业务合作伙伴提供更流畅的体验。

LXE Hearing is grounded in clinical excellence, drawing on both companies' exceptional clinical standards and scientific research, with more than 52 peer-reviewed articles validating the technology along with 68 patents.

LXE听力植根于临床卓越，依托两家公司的卓越临床标准和科学研究，拥有52篇以上的同行评审文章验证该技术，并持有68项专利。

hearX CEO and co-founder

hearX首席执行官兼联合创始人

Nic Klopper

尼可·克洛珀

will serve as CEO for LXE Hearing, with Eargo's COO and interim CEO

将担任 LXE Hearing 的首席执行官，Eargo 的首席运营官兼临时首席执行官

Bill Brownie

比尔·布朗尼

assuming the role of COO.

假设担任首席运营官的角色。

'The merger between Lexie and Eargo is founded on our shared mission to create hearing health solutions for everyone, everywhere,' said Klopper. 'Eargo's cutting-edge design, emphasis on clinical quality and customer-first approach to service perfectly complement hearX's suite of Bose-powered products and its award-winning mobile app.

“Lexie和Eargo的合并基于我们共同的使命，即为世界各地的每个人提供听力健康解决方案，”克洛珀说。“Eargo的尖端设计、对临床质量的重视以及以客户为中心的服务理念，完美地补充了hearX系列的Bose驱动产品及其屡获殊荣的移动应用程序。”

Together, we are going to revolutionize hearing aids and hearing health.'.

齐心协力，我们将彻底改变助听器和听力健康。

Eargo is recognized as a pioneer in direct-to-consumer hearing aids in the U.S., leading the industry with its highly coveted 'virtually invisible' design. With nearly a decade of success in digital hearing detection and diagnostics, hearX established its hearing aid division,

Eargo被公认为美国直销助听器领域的先驱，凭借其备受追捧的“几乎隐形”设计引领行业。hearX在数字化听力检测和诊断领域拥有近十年的成功经验，成立了其助听器部门。

Lexie Hearing

Lexie听力

, in 2020 and quickly established the #1 OTC hearing aid brand in the U.S.

，于2020年迅速成为美国第一的非处方助听器品牌。

'hearX and

'hearX 和

Lexie Hearing

Lexie听力

are a natural complement to Eargo,' said Brownie. 'The combination of our experience, talent and technology will make hearing health solutions more accessible and affordable for the estimated 44 million American adults who experience hearing loss.'

“是Eargo的天然补充，”布朗尼说。“我们的经验、人才和技术的结合将使听力健康解决方案对于大约4400万经历听力损失的美国成年人来说更加可及和负担得起。”

Patient Square Capital, a dedicated health care investment firm that invests in high-quality, growth-oriented health care companies, is backing the deal with an additional

专注于投资高质量、成长型医疗保健公司的专业医疗保健投资公司Patient Square Capital也在支持这笔交易，并追加了额外的投入。

$100 million

1亿美元

investment, reflecting investor confidence in the direct-to-patient hearing market, which continues to upend the traditional prescription model.

投资反映了投资者对直接面向患者的听力市场的信心，该市场持续颠覆传统的处方模式。

'The vast majority of American adults who suffer from hearing loss currently do not use hearing aids given historical barriers to access and shortcomings with traditional offerings,' said

“由于历史上的获取障碍和传统产品存在的不足，目前大多数患有听力损失的美国成年人并未使用助听器，”

Justin Sabet-Peyman

贾斯汀·萨贝特-佩曼

, Partner at Patient Square. 'We believe that LXE Hearing's innovative technology and unique go-to-market approach, enhanced by the synergies of the business combination, will provide unprecedented solutions to patients in need of hearing care.'

患者广场合伙人表示：“我们认为，LXE Hearing的创新技术和独特的市场推广方法，加上业务合并带来的协同效应，将为需要听力护理的患者提供前所未有的解决方案。”

For more information about LXE Hearing, please visit

有关 LXE 听证会的更多信息，请访问

www.lxehearing.com

。

Advisors

顾问

Lazard acted as sole financial advisor to hearX on the merger and capital raise. Ropes & Gray LLP acted as legal counsel to Patient Square Capital and Eargo.

拉扎德担任了hearX在合并和融资方面的独家财务顾问。Ropes & Gray LLP 担任了Patient Square Capital和Eargo的法律顾问。

About Eargo

关于Eargo

Eargo is a medical device company on a mission to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, complete-in-canal, FDA-regulated devices indicated to compensate for mild to moderate hearing loss.

Eargo是一家致力于改善听力健康的医疗设备公司。我们的创新产品和市场推广方法解决了传统助听器使用中的主要挑战，包括社会污名、可及性和成本。我们相信，Eargo助听器是首款几乎隐形、可充电、完全置于耳道内、经FDA监管的设备，适用于轻度至中度听力损失的补偿。

Eargo's differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online, at retail locations or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, e-mail or video chat. Eargo hearing aids are offered to consumers OTC without compromising the features, performance or support that we believe is vital to successfully integrating devices into our customers' lives.

Eargo的差异化、以消费者为中心的方法使消费者能够掌控自己的听力。消费者可以在线上、零售店或通过电话购买，并通过电话、短信、电子邮件或视频聊天获得听力专业人士提供的个性化且便捷的咨询和支持。Eargo助听器以非处方方式提供给消费者，同时不妥协我们认为对成功将设备融入客户生活至关重要的功能、性能或支持。

To learn more, please visit .

要了解更多信息，请访问。

https://www.eargo.com/

。

About hearX Group

关于hearX集团

hearX

听X

www.hearxgroup.com

is an industry-leading health technology company, with a suite of digital, clinically-validated, affordable and mobile technologies for hearing loss detection and diagnosis, for those who need it most. Founded in 2015, hearX technologies are now used in over 70 countries globally for early detection and intervention..

是一家行业领先的健康技术公司，拥有一系列数字的、经过临床验证的、价格合理的移动技术，用于听力损失的检测和诊断，服务于最需要这些技术的人群。公司成立于2015年，hearX的技术现已被全球超过70个国家用于早期检测和干预。

About Lexie Hearing

关于Lexie听力

Lexie Hearing

Lexie听力

https://lexiehearing.com/us

has been the #1 OTC hearing aid brand in the U.S. for two years running and was chosen for Inc.'s Best in Business List in Health Products in 2024 for its innovation, quality, and award-winning customer support.

连续两年蝉联美国第一大非处方助听器品牌，并因其创新、品质和屡获殊荣的客户支持，入选《Inc.》杂志2024年度商业健康产品最佳榜单。

Lexie Hearing

Lexie听力

was named among the 100 Most Influential Companies by TIME in 2023 for its innovative OTC hearing aid technology and meaningful impact on hearing health. Lexie products are clinically proven and are sold in more than 16,000 leading retail stores nationwide.

因其创新的非处方助听器技术和对听力健康的显著影响，被评为《时代》杂志2023年最具影响力的100家公司之一。Lexie产品经过临床验证，并在全国超过16,000家领先的零售店销售。

About Patient Square Capital

关于患者广场资本

Patient Square Capital is a dedicated health care investment firm with approximately

Patient Square Capital 是一家专注于医疗保健的投资公司，拥有大约

$12 billion

120亿美元

in assets under management as of

截至资产管理规模

December 31, 2024

2024年12月31日

. The firm aims to achieve strong investment returns by partnering with growth-oriented companies and top-tier management teams whose products, services, and technologies improve health. Patient Square utilizes deep industry expertise, a broad network of relationships, and a partnership approach to make investments in companies that will grow and thrive.

公司旨在通过与成长型公司和一流管理团队合作，实现强劲的投资回报，这些公司提供的产品、服务和技术能够改善健康状况。Patient Square利用深厚的行业专业知识、广泛的关系网络和合作方法，投资于那些将成长并壮大的公司。

Patient Square invests in businesses that strive to improve patient lives, strengthen communities, and create a healthier world. For more information, visit .

患者广场投资于致力于改善患者生活、加强社区建设以及创造更健康世界的业务。欲了解更多信息，请访问。

www.patientsquarecapital.com

。

*Source: Circana, LLC, Retail Tracking Service, US Dollar and Unit Sales,

*来源：Circana, LLC，零售追踪服务，美元和单位销售，

Aug 2023

2023年8月

July 2024

2024年7月

SOURCE LXE Hearing

来源：LXE听证会

WANT YOUR COMPANY'S NEWS